Panelists discuss how maintaining patients on effective single therapies for Crohn’s disease is preferable to switching between different mechanisms of action, while addressing access challenges ...
Company strategy: In discussions with multiple potential animal health company partners to expand the indication and commercialize Canalevia for treatment of general diarrhea globally SAN FRANCISCO, ...
The Alzheimer’s disease market is expected to grow at a high compound annual growth rate (CAGR) of 21.8% from $2.4bn in 2023 to $17bn by 2033. Image credit: Antonio Marca / Shutterstock.com Eli Lilly ...
The next-generation bispecific antibody market is advancing rapidly, with revenues expected to reach hundreds of millions between 2025 and 2034, reports Towards Healthcare a sister firm of Precedence ...
Metabolic dysfunction-associated steatotic liver disease is the most common liver disease in the world, affecting about one-third of the adult population. This disorder is characterized by the ...
Mumbai: Wockhardt has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (US FDA) for its novel antibacterial agent Zidebactam-Cefepime ...
Harmony Biosciences Holdings faces setbacks after a failed trial and sNDA rejection. Click here to find out why HRMY is a Hold.
The tiny fruit fly could have a mighty impact on identifying optimal treatments for people with alcohol use disorder. A new study confirmed that using fruit flies may help scientists understand the ...
DelveInsight’s, “Myocardial Infarction Pipeline Insight, 2025” report provides comprehensive insights about 30+ companies and 40+ pipeline drugs in Myocardial Infarction pipeline landscape. It covers ...
ABU DHABI, 30th September, 2025 (WAM) -- Sheikh Zayed bin Hamad Al Nahyan, Chairman of the National Drug Enforcement Authority, today received at the Authority’s HQ a delegation from the Arab Republic ...
GLIX1 restores TET2 activity in cancer, resulting in double stranded DNA breaks in cancer cells only - - FDA IND clearance received for Phase 1/2a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback